Your browser doesn't support javascript.
loading
Placental glycosylation senses the anti-angiogenic milieu induced by human sFLT1 during pregnancy.
Kirkgöz, Kürsat; Vogtmann, Rebekka; Xie, Yiran; Zhao, Fangqi; Riedel, Alina; Adam, Lisa-Marie; Freitag, Nancy; Harms, Charlotte; Garcia, Mariana G; Plösch, Torsten; Gellhaus, Alexandra; Blois, Sandra M.
Afiliação
  • Kirkgöz K; Department of Obstetrics and Fetal Medicine, Glycoimmunology Research Group, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
  • Vogtmann R; Department of Gynecology and Obstetrics, University Hospital Essen, Germany.
  • Xie Y; Department of Obstetrics and Fetal Medicine, Glycoimmunology Research Group, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
  • Zhao F; Department of Obstetrics and Fetal Medicine, Glycoimmunology Research Group, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
  • Riedel A; Department of Gynecology and Obstetrics, University Hospital Essen, Germany.
  • Adam LM; Department of Obstetrics and Fetal Medicine, Glycoimmunology Research Group, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
  • Freitag N; Department of Obstetrics and Fetal Medicine, Glycoimmunology Research Group, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
  • Harms C; Department of Obstetrics and Fetal Medicine, Glycoimmunology Research Group, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
  • Garcia MG; Department of Obstetrics and Fetal Medicine, Glycoimmunology Research Group, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
  • Plösch T; Department of Obstetrics and Gynaecology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands; Perinatal Neurobiology, Department of Human Medicine, School of Medicine and Health Sciences, Carlvon Ossietzky Universität Oldenburg, Oldenburg, Germany.
  • Gellhaus A; Department of Gynecology and Obstetrics, University Hospital Essen, Germany.
  • Blois SM; Department of Obstetrics and Fetal Medicine, Glycoimmunology Research Group, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. Electronic address: s.blois@uke.de.
J Reprod Immunol ; 164: 104284, 2024 Jun 18.
Article em En | MEDLINE | ID: mdl-38908337
ABSTRACT
Abnormal placental angiogenesis during gestation resulting from high levels of anti-angiogenic factors, soluble fms-like tyrosine kinase-1 (sFLT1) and soluble endoglin, has been implicated in the progression of preeclampsia (PE). This heterogeneous syndrome (defined by hypertension with or without proteinuria after 20 weeks of pregnancy) remains a major global health burden with long-term consequences for both mothers and child. Previously, we showed that in vivo systemic human (hsFLT1) overexpression led to reduced placental efficiency and PE-like syndrome in mice. Galectins (gal-1, -3 and -9) are critical determinants of vascular adaptation to pregnancy and dysregulation of the galectin-glycan circuits is associated with the development of this life-threatening disease. In this study, we assessed the galectin-glycan networks at the maternal-fetal interface associated with the hsFLT1-induced PE in mice. We observed an increase on the maternal gal-1 expression in the decidua and junctional zone layers of the placenta derived from hs FLT1high pregnancies. In contrast, placental gal-3 and gal-9 expression were not sensitive to the hsFLT1 overexpression. In addition, O- and N-linked glycan expression, poly-LacNAc sequences and terminal sialylation were down-regulated in hsFLT1 high placentas. Thus, the gal-1-glycan axis appear to play an important role counteracting the anti-angiogenic status caused by sFLT1, becoming critical for vascular adaptation at the maternal-fetal interface.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: J Reprod Immunol Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: J Reprod Immunol Ano de publicação: 2024 Tipo de documento: Article